The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models

Molecular Cancer Therapeutics

Volumn 5, Issue 9, 2006, Pages 2158-2164

  Ying, Han ^a   Biroc, Sandra L ^a   Li, Wei Wei ^a   Alicke, Bruno ^a   Xuan, Jian Ai ^a   Pagila, Rene ^a   Ohashi, Yasuhiro ^b   Okada, Toshiya ^c   Kamata, Yoichi ^c   Dinter, Harald ^a  

^a BAYER AG   (Germany)

^b Nihon Schering Kabushiki Kaisha   (Japan)

^c Osaka Prefecture University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FASUDIL; RHO KINASE INHIBITOR; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; BRAIN ISCHEMIA; BRAIN VASOSPASM; BREAST CANCER; CANCER INHIBITION; CELL GROWTH; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; RAT; SYMPTOM; TUMOR CELL; TUMOR VOLUME;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BREAST NEOPLASMS; CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; FEMALE; FIBROSARCOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, NUDE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RATS; RHO-ASSOCIATED KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33749538874     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0440     Document Type: Article

References (27)

1. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003;83:1325-58.
2. Zicha D, Dobbie IM, Holt MR, et al. Rapid actin transport during cell protrusion. Science 2003;300:142-45.
3. Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res 2000;261:44-51.
4. Redowicz MJ. Rho-associated kinase: involvement in the cytoskeleton regulation. Arch Biochem Biophys 1999;364:122-4.
5. Izawa I, Amano M, Chihara K, Yamamoto T, Kaibuchi K. Possible involvement of the inactivation of the Rho-Rho-kinase pathway in oncogenic Ras-induced transformation. Oncogene 1998;17:2863-71.
6. Ridley AJ. Rho proteins and cancer. Breast Cancer Res Treat 2004;84: 13-9.
7. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002; 2:133-42.
8. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999;81:682-7.
9. Burbelo P, Wellstein A, Pestell RG. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res Treat 2004;84:43-8.
10. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999;5:221-5.
11. Wicki A, Niggli V. The Rho/Rho-kinase and the phosphatidylinositol 3-kinase pathways are essential for spontaneous locomotion of Walker 256 carcinosarcoma cells. Int J Cancer 2001;91:763-71.
12. Hirose M, Ishizaki T, Watanabe N, et al. Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells. J Cell Biol 1998;141: 1625-36.
13. Imamura F, Mukai M, Ayaki M, Akedo H. Y-27632, an inhibitor of Rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn J Cancer Res 2000;91:811-6.
14. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 2000;269:652-9.
15. Nakajima M, Katayama K, Tamechika I, et al. WF-536 inhibits metastatic invasion by enhancing the host cell barrier and inhibiting tumour cell motility. Clin Exp Pharmacol Physiol 2003;30:457-63.
16. Nakajima M, Hayashi K, Egi Y, et al. Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother Pharmacol 2003;52:319-24.
17. Hirooka Y, Shimokawa H. Therapeutic potential of Rho-kinase inhibitors in cardiovascular diseases. Am J Cardiovasc Drugs 2005;5: 31-9.
18. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopi-perazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther 2002;93:225-32.
19. Tachibana E, Harada T, Shibuya M, et al. Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien) 1999;141:13-9.
20. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E. Fasudil Ischemic Stroke Study Group. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci 2005;238: 31-9.
21. Yamaguchi H, Kasa M, Amano M, Kaibuchi K, Hakoshima T. Molecular mechanism for the regulation of Rho-kinase by dimerization and its inhibition by fasudil. Structure 2006;14:589-600.
22. Nagumo H, Sasaki Y, Ono Y, Okamoto H, Seto M, Takuwa Y. Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am J Physiol Cell Physiol 2000;278: C57-65.
23. Hattori T, Shimokawa H, Higashi M, et al. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 2004;109:2234-9.
24. Glyn MC, Lawrenson JG, Ward BJ. A Rho-associated kinase mitigates reperfusion-induced change in the shape of cardiac capillary endothelial cells in situ. Cardiovasc Res 2003;57:195-206.
25. Nakajima M, Hayashi K, Katayama K, et al. Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions. Eur J Pharmacol 2003;459:113-20.
26. Sawada K, Morishige K, Tahara M, et al. Lysophosphatidic acid induces focal adhesion assembly through Rho/Rho-associated kinase pathway in human ovarian cancer cells. Gynecol Oncol 2002;87:252-9.
27. Nakagawa H, Yoshioka K, Miyahara E, Fukushima Y, Tamura M, Itoh K. Intrathecal administration of Y-27632, a specific Rho-associated kinase inhibitor, for rat neoplastic meningitis. Mol Cancer Res 2005;3:425-33.